Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors.

被引：7

作者：

Banerji, Udai ^{[1
]}

Ranson, Malcolm ^{[2
]}

Schellens, Jan H. M. ^{[3
]}

Esaki, Taito ^{[4
]}

Dean, Emma ^{[2
]}

Zivi, Andrea ^{[3
]}

van der Noll, Ruud ^{[3
]}

Stockman, Paul K. ^{[5
]}

Marotti, Marcelo ^{[5
]}

Garrett, Michelle D. ^{[1
]}

Davies, Barry R. ^{[5
]}

Elvin, Paul ^{[5
]}

Hastie, Andrew ^{[5
]}

Lawrence, Peter ^{[5
]}

Cheung, S. Y. Amy ^{[5
]}

Stephens, Christine ^{[5
]}

Tamura, Kenji ^{[6
]}

机构：

[1] Inst Canc Res, Sutton, Surrey, England

[2] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England

[3] Netherlands Canc Inst, Amsterdam, Netherlands

[4] Kyushu Natl Canc Ctr, Fukuoka, Japan

[5] AstraZeneca R&D, Macclesfield, Cheshire, England

[6] Natl Canc Ctr, Tokyo, Japan

来源：

关键词：

D O I：

10.1158/1538-7445.AM2013-LB-66

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LB66

引用

页数：2